Are the pills as effective as the injections?

Which pills exist

Two oral semaglutide products are on the US label. Rybelsus (7 and 14 mg daily) is approved for type 2 diabetes.^[1] The Wegovy 25 mg tablet, taken once daily, is approved for weight management and appears in the 2026 Wegovy label alongside the injection.^[2] There is no tirzepatide pill; Lilly's oral candidate (orforglipron) is a different molecule and not covered here.

What the tablet trial found

In the Wegovy label's Study 7 (the OASIS 4 trial), 307 adults with obesity or overweight and no diabetes took the 25 mg tablet or placebo for 64 weeks. Weight fell 13.6% on the tablet and 2.2% on placebo. 79.2% of the tablet group lost at least 5% of their weight (31.1% on placebo) and 63.0% lost at least 10% (14.4%).^[2]

Mean % body weight lost, drug vs placebo. Two separate trials; not a head-to-head comparison.^[2]

Comparing with the injection, carefully

13.6% at 64 weeks and 14.9% at 68 weeks look alike, and they probably are in the same range. But the trials enrolled different people in different years, and the only fair comparison is a trial that randomises people to pill or shot, which has not been done. Gut side effects with the tablet were in the same family as the injection; the EU product information reports nausea in 46.6% of tablet users in that trial.^[3]

The trade-offs

• Daily rule. Empty stomach, no more than 4 oz of water, then a 30-minute wait before food, drink or other pills, every day.^[1][2] For some people that is easy; for others it is the deciding factor.
• No needle. The obvious advantage, and for people with needle fear a real one.
• Same warnings. The boxed thyroid warning, the pancreatitis and gallbladder warnings, and the pregnancy advice apply to the tablet as to the injection.^[2]

Heard vs evidence

The short version

Questions to bring to your prescriber

Print these or screenshot them. They are conversation starters, not a checklist of things to do.

• Given my mornings and my other medicines, can I realistically follow the empty-stomach rule every day?
• Is the tablet or the injection the better fit for my situation, and is cost or coverage part of that answer?
• If I move from one form to the other, how is that handled?

Sources

Every number on this page traces to one of these. "Primary read" means the full paper or label was read; "abstract only" means only the abstract was available; "secondary" means the figure was taken from a named review.

1. Novo Nordisk / FDA. Rybelsus (oral semaglutide) prescribing information, revised 01/2026. label
2. Novo Nordisk / FDA. Wegovy (semaglutide) injection and tablets, prescribing information, revised 06/2026. label
3. European Medicines Agency. Wegovy summary of product characteristics (OASIS 4 adverse reactions). label · figure via Fewer Bites dossier

Related explainers

All 35 questions